Phase I trial of intravenous fenretinide (4-HPR) plus safingol in advanced malignancies

ConclusionCombination fenretinide plus safingol commonly causes hypertriglyceridemia and may be associated with cardiac events at higher safingol levels. Minimal activity in refractory solid tumors was observed.Trial registration numberNCT01553071 (3.13.2012).
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research